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Abstract K-Synuclein has been implicated in the pathogenesis
of Parkinson’s disease based on mutations in familial cases of the
disease and its presence in Lewy bodies. Here we show that over-
expression of wild-type human K-synuclein is sufficient to induce
inclusion formation in SH-SY5Y cells. In this cellular model,
proteasome inhibition leads to an increase of K-synuclein
accumulation in vivo without ubiquitylation. In accordance, we
find that in vitro, unmodified K-synuclein can be directly
degraded by the 20S proteasome. These findings suggest an
ubiquitin-independent mechanism of proteasomal degradation for
K-synuclein and other natively unfolded proteins. ß 2001 Pub-
lished by Elsevier Science B.V. on behalf of the Federation of
European Biochemical Societies.
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1. Introduction
K-Synuclein is a natively unfolded protein of uncertain
function that is abundantly expressed in human brain [1^3].
Genetic studies have identi¢ed two mutations in the K-synu-
clein gene in early-onset autosomal dominant Parkinson’s dis-
ease (PD) [4,5]. PD is characterized neuropathologically by
the presence of ¢lamentous inclusions known as Lewy bodies
(LB) and Lewy neurites [6]. K-Synuclein was found to be the
main component of LB ¢laments in PD, as well as in demen-
tia with LB (DLB) and in glial cytoplasmic inclusions of mul-
tiple system atrophy, which are referred to as the K-synuclei-
nopathies [7^9]. LB pathology and K-synuclein aggregation in
neurons may contribute mechanistically to their dysfunction
and degeneration as also suggested by animal models [10^13].
Although the mechanism by which K-synuclein accumulates in
neurons is largely unknown, impaired degradation could be
involved.
Conjugation of multiple copies of ubiquitin to cellular tar-
gets (ubiquitylation) is a central signal for proteolytic degra-
dation by the 26S proteasome complex [14]. The 26S protea-
some is composed of two 19S regulatory ‘caps’ in association
with a 20S core complex, the latter of which contains the
protease active site. Recent work has suggested a potential
in vivo role for the free 20S particle in the ubiquitin-independ-
ent degradation of oxidatively damaged proteins [15] or cer-
tain small relatively unfolded proteins such as the cyclin-de-
pendent kinase inhibitor p21WAF1=CIP1 [16].
The great abundance of ubiquitin-immunoreactivity in LB
has long been taken as evidence that altered function of the
ubiquitin-proteasome pathway is a primary suspect in PD
pathogenesis [17]. Consistent with this idea, genetic studies
of familial cases of PD and juvenile Parkinsonism have re-
vealed mutations in enzymes involved in this pathway [18,19]
and proteasomal function is impaired in sporadic cases of the
disease [20]. Moreover, impaired degradation of mutant K-
synuclein by the proteasome was shown in SH-SY5Y cells
[21]. However, the link between K-synuclein accumulation
into LB and proteasome impairment is complicated by the
fact that up to 10% of inclusions in K-synucleinopathies
were found to be negative for ubiquitin [8,9,22] and that K-
synuclein degradation by the proteasome has recently been
questioned [23].
To investigate K-synuclein degradation and the role of pro-
teasome impairment in K-synuclein accumulation, we pro-
duced stably transfected SH-SY5Y cells over-expressing
wild-type (wt) K-synuclein. We found that chronic inhibition
of the proteasome in vivo increases accumulation of non-ubiq-
uitylated K-synuclein. Furthermore, we show that K-synuclein
can be directly degraded by the 20S proteasome in an ubiq-
uitin-independent manner. These ¢ndings suggest that ubiqui-
tin conjugation is not an absolute requirement for protea-
some-mediated K-synuclein degradation and that proteasome
dysfunction could be related to non-ubiquitylated K-synuclein
inclusions that have been reported in K-synucleinopathies
[8,9,22].
2. Materials and methods
2.1. Cell culture
SH-SY5Y human dopaminergic neuroblastoma cells were main-
tained at 37‡C in 5% CO2 in Dulbecco’s modi¢ed Eagle’s medium
(Life Technologies), supplemented with 10% fetal calf serum (Life
Technologies) and 1% penicillin/streptomycin. For proteasome inhibi-
tion, cells were grown to 60^70% con£uency and treated for 24 and 48
h with 10 WM lactacystin (A⁄nity Research Products). K-Synuclein
half-life was investigated in transfected cells by inhibiting protein syn-
thesis with 50 Wg/ml cycloheximide (Sigma-Aldrich) for 6, 12 and 19 h.
2.2. Plasmid construction and transfection
Wt human K-synuclein cDNA was subcloned into pcDNA3+ (In-
vitrogen). For transfection, cells were grown to 60^80% con£uency,
exposed to 20 Wl of Lipofectin Reagent (Life Technologies) and 2 Wg
of plasmid DNA for 6 h in serum-free medium at 37‡C, 5% CO2.
G418 (Life Technologies) at 300 Wg/ml was added 48 h following
transfection for selection of stable cell lines.
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2.3. Immunoblotting
SH-SY5Y cells were lysed in RIPA bu¡er which contained a cock-
tail of protease inhibitors. Protein amount was determined using a
protein assay kit (Bio-Rad). For immunoblotting, 10^20 Wg of cell
lysates were loaded per lane and separated on 15% SDS^PAGE and
transferred onto Immobilon P (Millipore). After blocking with 1%
gelatine in TBS, blots were incubated overnight with polyclonal anti-
serum PER4 (1:1000) directed against the C-terminus of K-synuclein
or anti-human K-synuclein antibody LB509 (1:5000; Zymed). Bound
antibodies were visualized using the avidin^biotin^peroxidase method
and 3,3P-diaminobenzidine as substrate (Vectastain Elite kit, Vector
Laboratories). For anti-ubiquitin monoclonal antibody (1:500; Chem-
icon), anti-ubiquitin polyclonal antiserum (1:500; Dako) and anti-
LAPP (1:100; Boehringer Mannheim), membranes were incubated
in 5% milk in TBS and developed with peroxidase-conjugated rabbit
anti-mouse (1:2000) or goat anti-rabbit (1:5000) antiserum and en-
hanced chemiluminescence (NEN Life Science).
2.4. Immunocytochemistry
SH-SY5Y cells were ¢xed in 4% paraformaldehyde and incubated
overnight at 4‡C with anti-K-synuclein antisera PER4 (1:500), or
PER7 (against the ¢rst 120 amino acids; 1:1000) and anti-ubiquitin
polyclonal antiserum (1:1000; Dako) or monoclonal antibody (1:250;
Chemicon). Cells were then incubated for 2 h at room temperature
with biotinylated secondary antibody (Vector Laboratories), followed
by £uorescein-avidin (Vector Laboratories) for 1 h at room temper-
ature. Cell nuclei were visualized using 4P,6-diamidino-2-phenylindole
(DAPI; 1 ng/Wl ; Sigma-Aldrich). Fluorescence was analyzed using a
Leitz DMRB microscope.
2.5. Puri¢cation of inclusions and electron microscopy
The nature of K-synuclein inclusions was investigated by electron
microscopy of sarcosyl-extracted preparations as previously reported
for dispersed K-synuclein ¢laments from DLB brain [8]. For immu-
nogold labeling, antiserum PER4 (1:100) was used.
2.6. Proteasome activity assays
Cells treated with 10 WM lactacystin for 12, 24 and 48 h and un-
treated control cells were lysed in 50 mM Tris bu¡er, pH 7.4, con-
taining 5 mM ATP, 10 mM MgCl2, 1 mM DTT with repeated cycles
of freezing and thawing. Ten micrograms of protein from each lysate
were treated with or without lactacystin (10 WM ¢nal concentration)
and incubated for 2 h at 37‡C in 100 Wl of 10 mM Tris, pH 7.5,
containing 50 WM of the chymotryptic £uorogenic peptide substrate
syccinyl-Leu-Leu-Val-Tyr-AMC; (A⁄nity Research Products). The
reaction was terminated by the addition of 2 ml of 80 mM sodium
acetate, pH 4.5. Release of free AMC was determined using a Shi-
madzu RF-5000 spectro£uorophotometer (excitation 360 nm, emis-
sion 460 nm).
2.7. In vitro 20S proteasomal degradation of K-synuclein
Recombinant K-synuclein was expressed and puri¢ed as described
previously [3]. Puri¢ed human 20S proteasomes (0.5 nM; A⁄niti Re-
search) were incubated with K-synuclein (1.8 WM) in a ¢nal volume of
30 Wl of 25 mM Tris^HCl, pH 7.5, at 37‡C. At di¡erent time points,
5 Wl of reaction mixture was removed. Samples were separated on 5^
20% SDS^PAGE and transferred to nitrocellulose (Hybond C-Super;
Amersham). Membranes were blocked in 5% milk in TBS, and probed
with anti-human K-synuclein antibody LB509 (1:5000; Zymed) for 2 h
at room temperature. Blots were developed with peroxidase-conju-
gated rabbit anti-mouse antiserum (1:5000) and enhanced chemilumi-
nescence (NEN Life Science). As a control, human K-lactalbumin
(Sigma-Aldrich) was incubated with 20S proteasomes under identical
conditions to K-synuclein and blots were processed essentially as
above, except membranes were blocked in 0.1% BSA, and probed
with anti-human K-lactalbumin antiserum (1:15 000; Sigma-Aldrich).
2.8. Statistical analysis
To ascertain di¡erences among the various treatment groups of SH-
SY5Y cells, logistic regression analysis was performed to allow adjust-
ment for inter-experiment variation. All experiments were repeated
four times.
3. Results
3.1. Over-expression of wt K-synuclein in SH-SY5Y cells leads
to formation of intracellular inclusions
To study the metabolism and aggregation of wt K-synuclein
in vivo, we generated SH-SY5Y cell lines stably over-express-
ing untagged wt human K-synuclein. Immunoblotting analysis
con¢rmed that these cells signi¢cantly over-expressed K-synu-
clein compared to non-transfected cells and cells transfected
with empty vector (controls) as shown in Fig. 1e. Using a
panel of anti-K-synuclein antibodies, we found that control
cells showed a di¡use distribution of K-synuclein in the cell
soma (Fig. 1a). This was more intense in transfected cells 10^
15% of which showed K-synuclein-positive cytoplasmic inclu-
Fig. 1. K-Synuclein expression and accumulation in transfected SH-SY5Y cells. K-Synuclein staining in control (a) and stably transfected SH-
SY5Y cells (b,c) using anti-K-synuclein antisera PER7 (a,b) and PER4 (c). K-Synuclein inclusions were present in cell bodies (b) and processes
(c). Ultrastructurally, these inclusions were made of amorphous aggregates of K-synuclein as shown by immunogold electron microscopy (d)
performed with PER4 antiserum. In (e), an increase of K-synuclein expression in transfected cells (lanes 2 and 3) compared to control cells
(lane 1) is shown by immunoblotting using LB509 antibody. Endogenous, over-expressed and recombinant K-synuclein (lane 4) were detected
as 19 kDa bands, in accordance with the expected apparent molecular weight of full-length protein.
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sions (Fig. 1b, c). Control experiments where the primary
antibody was omitted did not show any immunoreactivity
(data not shown). In order to investigate the ultrastructural
characteristics of these inclusions, we performed electron mi-
croscopy and immunogold labeling in cell extracts, which
showed immunogold-labeled amorphous rather than ¢lamen-
tous material (Fig. 1d). No obvious toxicity was detected in
cells with inclusions using DAPI staining or MTT assays (data
not shown).
3.2. Proteasome inhibition in vivo leads to accumulation of
non-ubiquitylated K-synuclein
Fluorogenic assays showed signi¢cant proteasome inhibi-
tion in transfected cells even 48 h following treatment with
10 WM lactacystin (Fig. 2a), without signi¢cant toxicity as
assessed by MTT assays (data not shown). Using 10 WM lac-
tacystin for 48 h for chronic proteasome inhibition, we found
increased K-synuclein immunoreactivity on immunoblots of
lysates from treated cells over-expressing K-synuclein (Fig.
2b). Semi-quantitative analysis using densitometry (Scion Im-
age 1.62c Software, Scion Corp) showed a two-fold increase in
K-synuclein immunoreactivity after 48 h of proteasome inhi-
bition. No changes were observed after 24 h treatment. This is
consistent with the ¢nding that K-synuclein was remarkably
stable in our transfected cells for over 19 h, as shown by de
novo inhibition of protein synthesis with 50 Wg/ml of cyclo-
heximide. Under similar conditions, the short-lived LAPP pro-
tein used as control disappeared within the ¢rst 6 h (Fig. 2c).
Furthermore, complete proteasome inhibition led to accumu-
lation of poly-ubiquitylated substrates and disappearance of
free ubiquitin (Fig. 2d). However, in the same preparations,
no ubiquitylated K-synuclein was found either directly or fol-
lowing immunoprecipitation with anti-K-synuclein antibodies
(data not shown).
3.3. Proteasome inhibition increases the formation of
ubiquitin-negative K-synuclein inclusions
To investigate whether K-synuclein accumulation following
lactacystin treatment was linked to aggregation, we quanti¢ed
cells with K-synuclein-positive inclusions after inhibition of
the proteasome in vivo for 48 h. We found a two-fold increase
Fig. 2. Lactacystin treatment leads to accumulation of non-ubiquity-
lated K-synuclein. a: Graph indicating chymotryptic proteasomal ac-
tivity (arbitrary units) in cells treated with (+Lact) or without
(3Lact) lactacystin after 12, 24 and 48 h. b: Cells over-expressing
K-synuclein were treated (+) or not (3) with 10 WM lactacystin for
24 and 48 h and immunoblotted using antiserum PER4. Semi-quan-
titative analyses using densitometry revealed a two-fold increase in
the accumulation of K-synuclein only after 48 h. c: K-Synuclein and
LAPP expressions were analyzed by immunoblotting cell extracts
treated with cyclohexamide and tested at the indicated time points.
While K-synuclein is stable at all time points, LAPP is almost com-
pletely degraded within the ¢rst 6 h. d: Total protein lysates were
analyzed by immunoblotting with anti-ubiquitin antibodies before
(3) and after (+) lactacystin treatment. Note the accumulation of
poly-ubiquitin conjugates and the disappearance of free ubiquitin
following inhibition of the proteasome pathway.
Fig. 3. Proteasome inhibition increases the formation of ubiquitin-
negative K-synuclein-positive inclusions. a: A signi¢cant increase in
the percentage of cells with K-synuclein-positive inclusions was
found (P6 0.006, n = 4) in treated (K-syn cells +lact) compared to
untreated cells (K-syn cells 3lact) over-expressing K-synuclein. A
small number of cells with K-synuclein-positive inclusions were also
observed in treated control cells (control cells +lact). The increase
in inclusion number after lactacystin treatment was clearly demon-
strated with both PER7 (b) and PER4 (not shown) antisera. No in-
clusions were stained using either anti-ubiquitin polyclonal antise-
rum (c) or monoclonal antibody (not shown) before or after
lactacystin treatment.
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(P6 0.006, L-coe⁄cient = 40.9, 95% con¢dence interval 11.9^
70.02) in the percentage of cells with inclusions (Fig. 3a).
Interestingly, although cells over-expressing K-synuclein
showed signi¢cant increase in K-synuclein-positive inclusion
formation after lactacystin treatment (Fig. 3b), two di¡erent
well-characterized anti-ubiquitin antibodies failed to stain K-
synuclein inclusions (Fig. 3c), demonstrating that the aggre-
gated K-synuclein is not ubiquitylated.
3.4. K-Synuclein is degraded by puri¢ed 20S proteasomes
The accumulation of K-synuclein and the absence of poly-
ubiquitylated forms of the protein suggested that K-synuclein
could be degraded by the proteasome in vivo in an ubiquitin-
independent manner. Since K-synuclein is natively unfolded,
we hypothesized that the ‘unfoldase’ activity of the 19S regu-
lator may not be necessary for its proteasomal degradation.
We therefore performed an in vitro assay to determine
whether K-synuclein can be directly degraded by the 20S pro-
teasome. We incubated puri¢ed recombinant K-synuclein with
puri¢ed human 20S proteasomes and found that the 20S pro-
teasome was able to e⁄ciently degrade K-synuclein in an ubiq-
uitin-independent manner (Fig. 4a,b). This reaction was com-
pletely inhibited by the addition of 10 WM lactacystin (Fig.
4c). Under similar conditions, human K-lactalbumin, a tightly
folded protein of similar molecular size to K-synuclein, used as
control, was completely resistant to 20S proteasome degrada-
tion (Fig. 4d).
4. Discussion
Our data show that over-expression of wt K-synuclein in
SH-SY5Y cells is su⁄cient to induce its accumulation into
cellular inclusions. Furthermore, we ¢nd that inhibition of
the proteasome with lactacystin leads to an increase in soluble
and aggregated K-synuclein. However, neither K-synuclein nor
K-synuclein-positive inclusions were ubiquitylated before and
after proteasome inhibition, suggesting that ubiquitylation is
not an absolute requirement for proteasome-mediated K-syn-
uclein degradation. In agreement with these data, we ¢nd that
in vitro K-synuclein can be degraded by the 20S proteasome in
an ubiquitin-independent manner.
Whether the proteasome pathway is involved in K-synuclein
metabolism has been a matter of debate. An early study by
Bennett et al. [21] showed that K-synuclein transiently trans-
fected in SH-SY5Y cells is degraded by the proteasome. How-
ever, in their study, Bennett et al. [21] used very high concen-
trations (40 WM) of a lactacystin catabolite (L-lactone), which
could interfere with proteasome-unrelated activities as pointed
out by Ancolio et al. [23] who instead found that lower doses
of lactacystin (5 WM) did not a¡ect the metabolism of either
wt or mutant K-synuclein in HEK cells or murine neurons
over-expressing K-synuclein. Although it is possible that pro-
teasome-mediated K-synuclein degradation varies between dif-
ferent cell types, here we show that at low concentrations of
lactacystin, non-toxic for SH-SY5Y cells, chronic exposure
rather than shorter treatment enhances K-synuclein accumu-
lation. Accordingly, we observed an increase in the accumu-
lation of K-synuclein after 48 h rather than 24 h of protea-
some inhibition. This is consistent with the ¢nding that K-
synuclein in our cells was stable over 19 h after de novo in-
hibition of protein synthesis. In agreement with this remark-
able stability of cellular K-synuclein, a previous study reported
a very long half-life for K-synuclein in stably transfected cells
[24].
Interestingly, following lactacystin treatment, we only ob-
served increased non-ubiquitylated K-synuclein. A similar ob-
servation was previously reported by Bennett et al. [21] who
suggested that this could be due to concurrent de-ubiquityla-
tion of K-synuclein by isopeptidases. However, this is less
likely, since in our study we readily detected accumulation
of poly-ubiquitylated substrates after lactacystin treatment.
Instead, we show for the ¢rst time that K-synuclein can be
directly degraded by the 20S core of the proteasome in an
ubiquitin-independent manner.
K-Synuclein is a natively unfolded protein which only
adopts a helical conformation upon binding to lipid mem-
branes [25]. Because of its lack of secondary structure, it is
therefore possible that in vivo, unfolded K-synuclein could
bypass the need for ubiquitylation and unfolding by the 19S
regulator, and enter directly the 20S proteasome where it is
degraded. Consistent with this notion, recent reports have
shown that other unfolded proteins can be degraded by the
20S proteasome in an ubiquitin-independent manner [16,26].
Here we also show that unmodi¢ed full-length K-synuclein
over-expression in SH-SY5Y cells leads to accumulation into
ubiquitin-negative cytoplasmic inclusions and that this process
is further enhanced by inhibition of the proteasome pathway.
Several groups, using di¡erent cellular models, reported the
formation of K-synuclein-positive inclusions, which were var-
iably stained for ubiquitin [27,28]. More recently, Rideout et
al. [29] showed that proteasomal inhibition in non-transfected
PC12 cells leads to formation of ubiquitin-positive inclusions,
some of which contain K-synuclein which is not ubiquitylated.
Our observations suggest that ubiquitylation could be a late
Fig. 4. K-Synuclein is degraded by puri¢ed 20S proteasomes in an
ubiquitin-independent manner. Immunoblots were developed with
anti-K-synuclein antibodies (LB509; panels a^c) or anti-K-lactalbu-
min antibodies (panel d). a: Puri¢ed recombinant K-synuclein alone
(1.8 WM) is stable under the conditions of the degradation assay. b:
Addition of puri¢ed 20S proteasomes (0.5 nM) catalyzes rapid deg-
radation of recombinant K-synuclein, as assessed by loss of immu-
noreactivity. c: 20S proteasome-catalyzed degradation is completely
inhibited by the addition of lactacystin (10 WM). d: Under identical
conditions to a^c, puri¢ed human K-lactalbumin was completely re-
sistant to 20S proteasome degradation.
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event in K-synuclein accumulation. It is possible that K-synu-
clein is degraded in an ubiquitin-independent manner and
ubiquitylation occurs only when the protein becomes post-
translationally modi¢ed, for example glycosylated [30], or ab-
normally folded, e.g. aggregated into ¢laments. However, the
20S proteasome can directly degrade oxidatively damaged
proteins [15] and K-synuclein, which is nitrated in PD [31],
although post-translationally modi¢ed, in this case, could be
degraded by the 20S proteasome.
In K-synucleinopathies, K-synuclein degradation could be
defective or the proteasome could not cope with the increased
amount of protein leading to its accumulation. K-Synuclein
could accumulate initially in a non-ubiquitylated form and
subsequently becomes ubiquitylated, although there is yet no
direct biochemical proof that K-synuclein is ubiquitylated in
LB. A number of observations support the hypothesis of an
ubiquitin-independent degradation of K-synuclein in PD.
First, 20S function is impaired in PD [20] and 20S proteasome
is found in LB [32]. Second, up to 10% of all K-synuclein
inclusions in K-synucleinopathies are ubiquitin-negative. Fur-
thermore, the evolution of K-synuclein deposits in PD starts
with ubiquitin-negative cloud-like staining found in morpho-
logically normal neurons, progressing to more compact classic
LB usually immunoreactive for both K-synuclein and ubiqui-
tin [22].
Further studies are needed to clarify whether 20S protea-
some impairment in vivo is associated with accumulation of
K-synuclein in K-synucleinopathies.
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